Full-Time
Develops in vivo CAR T-cell therapies
$100k - $123.5k/yr
Senior
Lafayette, CO, USA
This position is required to be performed onsite at least 4 days a week in Louisville, CO.
Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to existing treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal of Umoja Biopharma is to enhance cancer treatment through its unique immunotherapy approach.
Company Size
51-200
Company Stage
Series C
Total Funding
$363M
Headquarters
Seattle, Washington
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Phone/Internet Stipend
The 2025 GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with groundbreaking new technologies. The contenders range from a newly formed startup to a leading U.S. cancer institute and companies in between. Joining the cohort is a business with technology to help healthcare providers better manage appointments and access to providers.This awards category recognizes pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for improving peoples’ lives and enhancing the healthcare system.The finalists are Archon Biosciences, DexCare, Fred Hutch Cancer Center, Talus Bioscience and Umoja Biopharma.Last year’s winner was CalmWave, a Seattle health-tech startup that created a system for making sense of the alarms triggered by the devices that monitor hospital ICU patients.Continue reading for details on each of this year’s finalists, and vote here or below.Archon BiosciencesArchon Biosciences emerged from stealth last October with $20 million in funding. The Seattle biotech company is running with technology developed in the lab of University of Washington biochemist and Nobel Prize winner David Baker.Archon’s proprietary protein structures, known as Antibody Cages or AbCs, combine two biomedical tools — naturally occurring antibodies and custom-designed proteins — to create a single new protein structure. These protein structures, or AbCs, are optimized with the aid of generative AI to travel in the body in controllable ways and engage with target cells in a more specific manner.“What we like to say is, it’s not whether you’re given a drug, it’s how you’re given it,” said CEO and co-founder James Lazarovits
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Smith, CFO of Starbucks. (LinkedIn Photo)— Starbucks announced Cathy Smith as its chief financial officer. Smith was most recently at Nordstrom for two years, and has held CFO roles at Bright Health, Target, Express Scripts, Walmart and others. Her longest role was at the defense and space juggernaut Raytheon.Smith succeeds Rachel Ruggeri, who was at Starbucks for more than two decades, ascending to the CFO role in 2021.The coffee giant announced layoffs of 1,100 corporate employees, including 612 in Seattle. It marks one of Starbucks’ largest layoffs and comes as CEO Brian Niccol turns to tech to help turn around the slumping business after taking over in September.— Avanade, a Seattle-based tech consulting and services company, announced a slate of C-suite hires
Umoja Biopharma announced a $100 million Series C financing to advance its in vivo CAR T cell therapy pipeline. The round was co-led by Double Point Ventures and DCVC Bio, with participation from investors like ARK Invest and SoftBank Vision Fund 2. The funds will support clinical development, including the lead CD22 UB-VV400 program. Campbell Murray, M.D., joins the Board of Directors. This financing highlights Umoja's potential to innovate in oncology and autoimmune treatments.
Umoja Biopharma announces oversubscribed $100 million Series C financing to advance in vivo CAR T pipeline through key oncology clinical milestones.
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing.